CLEC12A and lymphoma: Depleting more mature physiologic hematopoietic cells while sparing physiologic HSCs as predicted for CLL-1 targeting should pose less a problem, as evident in long-established therapies such as the depletion of mature B cells in CD20+ B cell leukemia/lymphoma.